肾细胞癌健康相关生活质量评估:范围综述
该范围综述系统检索1950至2023年肾细胞癌临床试验中使用的健康相关生活质量患者报告结局量表(PROMs),共纳入48项研究,多数为随机对照设计(34项,71%)并评估全身治疗(38项,79%)。研究使用27种不同PROMs(最多6种,中位数2种),仅4种(15%)为肾癌专用,46%的试验未使用任何肾癌特异性PROM。结论认为PROMs种类繁多且异质性大,妨碍跨试验比较,需修订肾癌特异性PROMs并规范其整合。
要点
- 48项肾细胞癌临床试验使用27种不同PROMs,中位数每项试验使用2种。
- 仅4种(15%)PROMs为肾癌专用,46%的试验未使用任何肾癌特异性PROM。
- 最常用量表包括EQ-5D、EORTC QLQ-C30、FKSI-15/19、FKSI-DRS和FACT-G。
核心结论
- 肾细胞癌临床试验中使用的PROMs种类繁多,妨碍跨试验的可解释性。
- 所用PROMs在评估领域及问题转化为问卷条目的方式上存在差异。
- 虽存在肾癌特异性PROMs,但其与患者的相关性存在缺陷。
- 为回答预设的健康相关生活质量研究问题,需修订肾癌特异性PROMs并规范其整合入临床试验。
研究设计与样本
- 范围综述,系统检索MEDLINE、Web of Science、PsychINFO、Academic Search Elite、CINAHL、Embase和Cochrane Library。
- 检索1950年至2023年发表的、纳入肾细胞癌患者并使用PROMs的临床试验原创同行评议文章。
- 提取预设试验特征及所用PROMs信息,计算分类数据的频数和比例、连续变量的范围和 median。
- 共纳入48项唯一研究。
主要发现
- 48项研究中,多数为随机对照设计(34项,71%)并评估全身治疗(38项,79%)。
- 试验共使用27种不同PROMs(最多6种,中位数2种),仅4种(15%)为肾癌患者专用。
- 46%的试验未使用任何肾癌特异性PROM。
- 最常用问卷为EQ-5D、EORTC QLQ-C30、FKSI-15/19条目版、FKSI-DRS和FACT-G。
- 最常评估的问题为疼痛、工作能力、疲乏、担忧和睡眠质量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: In oncology, patient-reported outcome measures (PROMs) capturing health-related quality of life (HRQOL) play an increasing role in clinical trials, drug approval, and policy making. This scoping review aimed to identify and elaborate on HRQOL-focussed PROMs used in renal cell cancer (RCC) clinical trials. METHODS: MEDLINE, Web of Science, PsychINFO, Academic Search Elite, CINAHL, Embase, and the Cochrane Library were searched systematically for original peer-reviewed articles on clinical trials including RCC patients and using PROMs, published between 1950 and 2023. Prespecified trial characteristics and information on the PROMs used were extracted. Frequencies and proportions of categorical data, and ranges and medians of continuous variables were calculated. KEY FINDINGS AND LIMITATIONS: Of the 48 unique studies included, the majority followed a randomised controlled design (34, 71%) and evaluated systemic treatments (38, 79%). The trials used 27 different PROMs (max = 6, median = 2), of which only 4 (15%) were developed specifically for kidney cancer patients. Of the trials, 46% did not use any RCC-specific PROM. European Quality of Life-5 Dimensions (EQ-5D), European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30), Functional Assessment of Cancer Therapy Kidney Symptom Index (FKSI) -15/19-item version, FKSI-Disease Related Symptoms, and Functional Assessment of Cancer Therapy-General (FACT-G) were the most frequently used questionnaires, with pain, ability to work, fatigue, worry, and sleep quality being the most commonly assessed issues. CONCLUSIONS AND CLINICAL IMPLICATIONS: A variety of PROMs are used in RCC patients, hindering interpretability across trials. The PROMs used differ in terms of both the domains assessed and how the issues are translated into questionnaire items. Though RCC-specific PROMs exist, these have flaws in terms of relevance to patients. To answer predefined relevant HRQOL research questions, revised RCC-specific PROMs and standardisation of their integration into clinical trials are warranted. PATIENT SUMMARY: Researchers are more and more interested in the health-related quality of life of kidney cancer patients and use questionnaires to measure it. This review shows that there are many different health-related quality of life questionnaires that are used in different combinations in clinical trials for kidney cancer patients. This makes it very difficult to compare these study results and draw reliable conclusions for the actual clinical treatment. It was even found that some of the questionnaires used do not capture things that patients actually consider important (eg, emotional issues such as dealing with thoughts about cancer and depression). Therefore, more work needs to be done to develop questionnaires that ask what is really important to kidney cancer patients' health-related quality of life. If these questionnaires are used in a consistent way in clinical trials, the results can be better compared. This will help treat kidney cancer patients in the best possible way.
引用
- Gross F, Rasmussen IML, Beisland EG, et al. Health-related Quality of Life Assessment in Renal Cell Cancer: A Scoping Review. Eur Urol Oncol. 2024. PMID: 39366818. doi:10.1016/j.euo.2024.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。